Data from a late-stage trial of the most advanced of a new class of drugs targeting the hepatitis C virus protease fuel hopes for major improvements in treatment outcomes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Opar, A. Excitement grows for potential revolution in hepatitis C virus treatment. Nat Rev Drug Discov 9, 501–503 (2010). https://doi.org/10.1038/nrd3214
Issue Date:
DOI: https://doi.org/10.1038/nrd3214
This article is cited by
-
Celastrol attenuates hepatitis C virus translation and inflammatory response in mice by suppressing heat shock protein 90β
Acta Pharmacologica Sinica (2023)
-
2010 in reflection
Nature Reviews Drug Discovery (2011)